Hydroxyurea with Thalidomide  Combination therapy in a Rare Case of  JAK2 mutation (JAK2V617F) and BCR–ABL  Positive Myelofibrosis

Swati Dasgupta; Ashis Mukhopadhyay; Soma Mukhopadhyay

Volume : III, Issue : I, January - 2014

Hydroxyurea with Thalidomide Combination therapy in a Rare Case of JAK2 mutation (JAK2V617F) and BCR–ABL Positive Myelofibrosis

Swati Dasgupta, Ashis Mukhopadhyay, Soma Mukhopadhyay

Abstract :

Myelofiosis is a fatal disease that accounts for 1% of all cancers and 10% of hematological malignancies. In this report coexistence of JAK2 V617F mutation with BCR ABL positive myelofiosis was noticed. Hydroxyurea therapy along with Thalidomide treatment induced normalization of the patient�s blood parameters (Complete haematological response) was seen after six months including cytogenetic and molecular remission where as Imatinib did not show the expected outcome. No detectable BCR-ABL fusion transcript in the bone marrow was found and spleen came to its normal condition. Hydroxyurea is a tyrosine kinase inhibitor that�s why it shows a good response to inhibitions of Janus kinase 2 mutation because JAK2 and ABL both are kinase domain mutations . We can conclude that hydroxyurea with Thalidomide is a good alternative of JAK 2 inhibitor in patients suffering from Myelofiosis.